Skip to main content
. 2021 Mar 14;128(6):747–757. doi: 10.1111/bcpt.13573

FIGURE 1.

FIGURE 1

The combination of BFOV and metformin improves impaired glucose homeostasis and insulin sensitivity in HFC57 mice. (A) Fasting blood glucose during the treatment. (B) Fasting blood insulin levels on 42‐days of treatment. (C) Homeostatic (HOMA) model based on fasting glucose and fasting insulin on 42‐days of treatment, HOMA‐IR = [glucose] (mmol/L) × [insulin] (µIU/mL)/22.5). (D, E) Blood glucose levels and area under the curve (AUC) in the ITT after 2‐weeks treatment. (F) AUC in the OGTT after 6‐weeks treatment. Nor, saline‐treated C57BL/6J mice. The statistics were performed with each single time point compared to Con group in Figure 1A and 1D. Con, saline‐treated HFC57 mice. BFOV, 20 mg/kg BW BFOV‐treated HFC57 mice. Met, 100 mg/kg BW metformin‐treated HFC57 mice. BFOV + Met, 20 mg/kg BW BFOV and 100 mg/kg BW metformin treated HFC57 mice. n = 8‐9/group. Values are means ± SEM. One‐way ANOVA: * P <.05, ** P <.01, *** P <.001 vs. Con. # P <.05, ## P <.01, ### P <.001 vs. BFOV + Met